Back to results
US 2017/0319688 A1Published application
Anti-rspo3 antibodies and methods of use
AssigneeGenentech, Inc.
InventorElaine Storm
Life of this patent
Estimating the term…
Abstract
Provided herein are anti-RSPO3 antibodies and methods of using the same.
Claims29
An isolated antibody that binds to human R-spondin 3 (RSPO3), wherein the antibody comprises:
- (a) a light chain variable region (VL) comprising (i) a first light chain hypervariable region (HVR-L1) comprising the amino acid sequence of SEQ ID NO:5, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:6, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:7;
- and a heavy chain variable region (VH) comprising (i) a first heavy chain hypervariable region (HVR-H1) comprising the amino acid sequence of SEQ ID NO:8, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:9, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:10;
- (b) a VL comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:11, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:12, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:13;
- and a VH comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:14, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:15, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:16;
- or
- (c) a VL comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:17, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:18, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:19;
- and a VH comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:20, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:21, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:22.
4 more elements
An isolated antibody that binds to human RSPO3, wherein the antibody has one or more of the following characteristics:
- (a) binds human RSPO3 but not human RSPO1, human RSPO2, or human RSPO4;
- (b) binds to human RSPO3 with a Kd of less than 0.5 nM;
- (c) binds to cynomolgus RSPO3 with a Kd of less than 0.5 nM;
- (d) binds to murine RSPO3 with a Kd of less than 0.5 nM;
- (e) binds human RSPO3 with a Kd of less than 1.0 nM, binds cyno RSPO3 with a Kd of less than 1.0 nM, and binds murine RSPO3 with a Kd of less than 1.0 nM;
- (f) binds human RSPO3 with a Kd of less than 0.5 nM, binds cyno RSPO3 with a Kd of less than 0.5 nM, and binds murine RSPO3 with a Kd of less than 0.5 nM;
- (g) has a half-life of at least 6 days following a single 10 mg/kg intravenous administration in cynomolgus monkeys;
- and
- (h) reduces tumor growth in a patient derived mouse xenograft RSPO3 fusion model, such as a PTPRK-RSPO3 fusion model, such as a PTPRK(exon1)-RSPO3(exon2) fusion or a PTPRK(exon7)-RSPO3(exon2) fusion model.
6 more elements
-9. (canceled)
-13. (canceled)
-22. (canceled)
-42. (canceled)
-49. (canceled)
Dependencies are inferred from the claim text.